"The voice for cancer physicians and their patients in Massachusetts."
On September 1st, 2016 the U.S. Food and Drug Administration approved BLINCYTO® (blinatumomab) for use in pediatric patients with relapsed or refractory Ph-negative B cell precursor Acute Lymphoblastic Leukemia. Read more.
Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451
Waltham, MA. 02451